WWWenjun Wu

Wenjun Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenjun Wu has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Zhen Cai

    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    5 shared publications
  • Xiaoyan Han

    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    3 shared publications
  • Baodong Ye

    Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

    2 shared publications
  • Donghua He

    Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang, China

    2 shared publications
  • Fei Chen

    Department of Hematology, Haining People’s Hospital, Jiaxing, Zhejiang, China

    2 shared publications
  • Gang Wang

    Department of Hematology, Quzhou People’s Hospital, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou, Zhejiang, China

    2 shared publications

Latest Publications

  • Clinical features and outcomes of spinal involvement in lymphoma: a single-center retrospective study

    by Ruyi Xu, Jia Hu, Xi Huang, Jinuo Wang, Xiaoyan Han, Mi Shao, Xinyi Teng, Zhen Cai, Wenjun Wu

  • Open Access

    Angioimmunoblastic T-cell lymphoma following Castleman’s disease: diagnostic challenges and literature review

    by Ruyi Xu, Xi Huang, Jia Hu, Jinuo Wang, Duoduo Zhao, Xiaoyan Han, Zhen Cai, Wenjun Wu

    Castleman disease (CD) represents a heterogeneous group of hematologic disorders characterized by distinct histopathological features. While CD is regarded as a pre-lymphomatous condition, its reactive or neoplastic nature is still a matter of controversy. Although rare, lymphoma has been reported in patients with CD, most commonly B-cell lymphomas. Here, we present a case of a 69-year-old man initially diagnosed with CD who subsequently developed angioimmunoblastic T-cell lymphoma (AITL) during treatment. To elucidate the potential biological relationship between these two disease entities, we performed whole-exome sequencing to compare genomic alterations between the two disease states. Additionally, we provide a concise review of published cases documenting lymphoma occurring after or coexisting with CD, summarizing patients’ characteristics and the various treatment strategies employed thus far.

  • Dual-readout autonomous biosensor integrating rolling circle amplification-DNAzyme walker, 3D DNA scaffold, and heterojunction electrode for femtomolar leukemia biomarker detection

    by Xiaoling Yu, Bingtao Fu, Lili Hong, Bei Zhang, Haili Zhou, Ying Zhu, Pingping Shao, Ruilan Gao, Ke-Jing Huang, Yuefeng Zhang, et al.


  • Open Access

    Prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma

    by Yi Zhong, Mengmeng Dong, Fang Yu, Yi Zhao, Lixia Zhu, Fengping Zhou, Wenjun Wu, Yi Li, Fangshu Guan, Linlin Huang, et al.

    The prognostic role of Epstein-Barr virus (EBV) DNA in aggressive angioimmunoblastic T-cell lymphoma (AITL) remains unclear. This study aimed to investigat

  • Open Access

    15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study

    by Binbin Lai, Chen Mei, Xiao Yan, Lieguang Chen, Yi Wang, Lixia Sheng, Shanhao Tang, Liping Mao, Ping Zhang, Yongcheng Sun, et al.

    Background: Higher-risk myelodysplastic syndromes (HR-MDS) carry a high risk of progression to acute myeloid leukemia and poor overall survival. Hypomethylating agents (HMAs), such as azacitidine, remain the standard of care but have limited efficacy. A 15-day venetoclax-azacitidine regimen has shown promising objective response rates (ORR) and potential as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in relapsed/refractory HR-MDS. We conducted a prospective multicenter trial to evaluate its efficacy and safety in previously untreated patients. Methods: This multicenter prospective study enrolled treatment-naïve HR-MDS patients (IPSS-R > 3.5). Venetoclax was administered on days 1–15 (escalated from 100 to 400 mg), combined with azacitidine (75 mg/m2) on days 1–7 of each 28-day cycle. The primary endpoint was ORR (2006 IWG criteria); secondary endpoints included complete remission (CR), overall survival (OS), and AML progression. Results: Twenty-eight patients (median age: 63 years) were enrolled, with a median follow-up of 8.5 months. ORR was 85.7% per 2006 IWG (CR: 35.7%, marrow CR: 50.0%), and 78.6% per 2023 IWG (CR: 35.7%). Responses were consistent across molecular and IPSS-R subgroups. Median OS was not reached. High neutrophil count and high cytogenetic risk were favorable factors; TP53 mutation/deletion was an adverse prognostic marker. Grade 3–4 hematologic toxicities included neutropenia (96.4%), anemia (71.4%), and thrombocytopenia (64.3%). Serious adverse events (35.7%) were mainly infections. No dose-limiting or unexpected toxicities were observed. Conclusions: The 15-day venetoclax plus azacitidine regimen demonstrated high efficacy and manageable toxicity in treatment-naïve HR-MDS. It may be particularly beneficial for patients with high neutrophil counts, adverse cytogenetics, or those eligible for HSCT, supporting further investigation in larger trials.

  • Open Access

    Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study

    by Ji-Nuo Wang, Chenyun Wang, Jinping Ying, Gaofeng Zheng, Xiaoyan Han, Peng An, Gang Wang, Fei Chen, Li Yang, Yang Yang, et al.

    Background: Patients with multiple myeloma (MM) and renal impairment (RI), particularly those requiring dialysis, have historically experienced poor outcomes. Despite advancements in targeted therapies, the prognosis of dialysis-dependent MM and factors influencing dialysis independence remain unclear. Objectives: This study aimed to provide a comprehensive analysis of the clinical manifestations and treatment outcomes of dialysis-dependent MM patients in China, and to explore the factors associated with dialysis independence and long-term survival. Design: We conducted a multicenter, retrospective, real-world cohort study. Methods: This multicenter, retrospective study included 122 MM patients requiring chronic hemodialysis (⩾28 days of treatment) at 4 comprehensive hospitals in China from January 2012 to November 2023. Hemodialysis resulting from causes other than MM was excluded. Logistic regression was employed for multivariate analysis of factors associated with dialysis independence, and Kaplan–Meier survival curves and Cox proportional hazard models were utilized for survival analysis. Results: Among the 122 patients, 74 patients (60.7%) were male, with a median age of 65 (39–87) years. Of these, 71.3% ( n = 87) had newly diagnosed MM (NDMM), and 28.7% ( n = 35) had relapsed/refractory MM (RRMM). Dialysis independence was achieved in 27 patients (22 with NDMM and 5 with RRMM). Proteasome inhibitors were used in 80.3% of patients ( n = 98), while 13.9% ( n = 17) received daratumumab-based regimens. After a median follow-up of 43.7 months, the median progression-free survival (PFS) was 14.4 months (95% confidence interval (CI): 3.6–25.2), and the median overall survival (OS) was 27.4 months (95% CI: 6.9–47.9). Dialysis-independent patients had significantly longer PFS (36.7 vs 9.4 months, p = 0.006) and OS (62.6 vs 17.7 months, p < 0.001). Factors associated with dialysis independence included achieving a very good partial response (VGPR), receiving daratumumab-based regimens, reduction in serum-free light chain ⩾80% after the first chemotherapy cycle, and age <65 years. Conclusion: In the era of new drugs, dialysis-dependent MM still has a poor prognosis, although dialysis independence improves survival.


  • Open Access

    N6-methyladenosine-mediated upregulation of H19 promotes resistance to bortezomib by modulating the miR-184/CARM1 axis in multiple myeloma

    by Gang Wang, Wenping Wu, Donghua He, Jiaheng Wang, Hongwei Kong, Wenjun Wu

    Malignant plasma cell proliferation characterizes multiple myeloma (MM), a hematologic disease. Bortezomib (BTZ) is a protease inhibitor that has been approved for the treatment of MM. Nevertheless, the effectiveness of BTZ is frequently impeded by drug resistance, and the mechanisms responsible for this phenomenon remain incompletely understood. A growing body of evidence indicates that N6-methyladenosine (m6A) plays crucial roles in a wide range of biological functions. However, the impact of m6A on the response of MM cells to BTZ is poorly understood. In our recent research, we discovered that METTL3 facilitated the m6A alteration of lncRNA H19, providing MM cells with resistance to BTZ. Additional examination revealed that H19 functioned as a sponge to negatively regulate the expression of miR-184 in MM cells. Furthermore, we discovered that H19 binds to miR-184, a tumor suppressor, in MM cells. In MM cells, miR184 can suppress the expression of CARM1 by targeting its 3′-UTR. In conclusion, rescue trials have validated the significance of the METTL3/H19/miR-184/CARM1 pathway in determining the susceptibility of cells to BTZ. Consequently, directing efforts toward this pathway could prove to be a powerful approach for enhancing the effectiveness of BTZ for MM therapy.


  • Open Access

    Overexpression of CISD2 alleviates septic acute kidney injury via activating Sonic Hedgehog signaling pathway

    by Wenjun Wu, Jia Zhang, Fei Chen, Hongzhuan Song, Xiujie Zhou

    Patients with sepsis are often complicated by acute kidney injury (AKI), which greatly increases mortality. In this study, our purpose was to explore the expression and function of CDGSH iron sulfur domain 2 (CISD2) in septic AKI, and the underlying molecular mechanism. Western blot and quantitative real-time polymerase chain reaction (RT-PCR) were employed to detect protein and mRNA levels in cells. The inflammation level of cells was evaluated by detecting the content of inflammatory factors (TNF-α, IL-1β, IL-6). Apoptosis of cells was evaluated by Caspase-3 activity assay, flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP Nick-End Labeling (TUNEL) staining. CISD2 was down-regulated in HK-2 cells treated with lipopolysaccharide (LPS). LPS treatment increased the level of inflammatory factors, the activity of Caspase-3, and the rate of apoptosis in HK-2 cells. However, overexpression of CISD2 significantly suppressed these effects. Moreover, overexpression of CISD2 activated the Sonic Hedgehog (SHH) signaling pathway. The use of cyclopamine (Cyc), a SHH signaling pathway inhibitor, eliminated the effect of overexpressing CISD2, that is, inhibiting LPS-induced inflammation and apoptosis of HK-2 cells. LPS treatment down-regulated CISD2 in HK-2 cells, and overexpression of CISD2 could inhibit LPS-induced inflammation and apoptosis of HK-2 cells by activating the SHH signaling pathway.


  • Follicular helper T cells: emerging roles in lymphomagenesis

    by Ji-Nuo Wang, Gaofeng Zheng, Wenjun Wu, He Huang

    Follicular helper T cells (Tfh) are a subset of CD4+ T cells that are fundamental to forming germinal centers, which are the primary sites of antibody affinity maturation and the proliferation of activated B cells. Tfh cells have been extensively studied over the past 10 years, especially regarding their roles in cancer genesis. This review describes the characteristics of normal Tfh cells and focuses on the emerging link between Tfh cells and lymphomagenesis. Advances in lymphoma genetics have substantially expanded our understanding of the role of Tfh cells in lymphomagenesis. Moreover, we detail a range of agents and new therapies, with a major focus on chimeric antigen receptor T-cell therapy; these novel approaches may offer new treatment opportunities for patients with lymphomas.


  • Open Access

    Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients

    by Xiaoyan Yue, Donghua He, Gaofeng Zheng, Yang Yang, Xiaoyan Han, Yi Li, Yi Zhao, Wenjun Wu, Qingxiao Chen, Enfang Zhang, et al.

    Extramedullary relapse of multiple myeloma (MM) is often resistant to existing treatments, and has an extremely poor prognosis, but our understanding of extramedullary relapse is still limited. The incidence, clinical characteristics, impact on the prognosis of extramedullary relapse, and the risk factors for extramedullary relapse in NDMM patients were analyzed. Among the 471 NDMM patients, a total of 267 patients had disease relapse during follow-up, including 64 (24.0%) patients with extramedullary relapse. Extramedullary relapse was more common in patients with younger age, IgD subtype, elevated LDH, extensive osteolytic lesions, extramedullary involvement, and spleen enlargement at the time of MM diagnosis. Survival analysis showed that extramedullary relapse patients had significantly worse median OS than patients with relapse but without extramedullary involvement (30.8 months vs. 53.6 months, p = 0.012). Multivariate analysis confirmed that elevated LDH (OR = 2.09, p = 0.023), >2 osteolytic lesions (OR = 3.70, p < 0.001), extramedullary involvement (OR = 3.48, p < 0.001) and spleen enlargement (OR = 2.27, p = 0.011) at the time of MM diagnosis were independent risk factors for extramedullary relapse in NDMM patients. Each of the above four factors was assigned a value of 1 to form the extramedullary relapse prediction score, and the 3-year extramedullary relapse rates of patients in the 0–2 and 3–4 score groups were 9.0 % and 76.7 %, respectively. This study suggested that extramedullary relapse was associated with poor clinical characteristics and poor prognosis in NDMM patients. The extramedullary relapse prediction score model composed of LDH, osteolytic lesions, extramedullary involvement and spleen enlargement has a better ability to predict extramedullary relapse than the existing ISS and R-ISS stages.